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The domain structure of human plasma fibronectin 
was investigated by limited proteolysis with trypsin 
and thermolysin with special emphasis on the compar- 
ison with  hamster plasma fibronectin. Both human and 
hamster plasma fibronectins gave closely spaced dou- 
blet bands on NaDodS04-polyacrylamide gels after  re- 
duction, but the spacing between these  two bands was 
significantly smaller in human plasma fibronectin. 
Thermolysin digestion of human plasma fibronectin 
produced a similar set of fragments as hamster plasma 
fibronectin, le. Mr = 155,000 (155K), 145,000 (145K), 
44,000  (44K),  24,000  (24K), and 22,000  (22K) fragments. 
The binding properties of these fragments are also 
identical with those from hamster plasma fibronectin. 
However, tryptic digestion of human plasma fibronec- 
tin gave a slightly different fragmentation profile than 
that of hamster plasma fibronectin. Human plasma 
fibronectin was cleaved into 215K,  185K,  32K, and 37K 
fragments, of which the  first  three  fragments were also 
generated from hamster plasma fibronectin but the 37K 
fragment was not. Time course analysis of tryptic 
digestion of human plasma fibronectin suggested that 
the 37K fragment was derived from large (a)  subunit 
together with the 32K and  the 185K fragments whereas 
small (/3) subunit was cleaved into  the 215K and the 
32K fragments. The human plasma fibronectin-specific 
37K fragment  was shown to be composed of the “Fib- 
2” domain which is represented by the 22K thermolysin 
fragment, because (i) the 37K tryptic fragment was 
degraded to  the 22K fragment by thermolysin, (ii) the 
binding properties  to fibrin, heparin, and gelatin of the 
37K fragment were identical with those of the 22K 
thermolysin fragment, and (iii) affinity-purified anti- 
37K antibodies specifically reacted with the 22K frag- 
ment as well as the 37K tryptic fragment. In addition, 
the anti-37K antibodies also reacted with the  tryptic 
215K fragment but not with the  tryptic 185K fragment, 
suggesting that only the 215K fragment contains the 
Fib-2 domain of the /3 subunit, while the 185K fragment 
was lacking the Fib-2 domain of the a subunit which 
was identified as the 37K fragment. In support of this 
view, only the 215K fragment could bind to fibrin. 
Furthermore,  the antibodies also reacted with the 155K 
thermolysin fragment but not with the 145K. This in- 
dicates that  the 37K tryptic fragment contains not only 
the Fib-2 domain but also the COOH-terminal 10K re- 
gion of the 155K thermolysin fragment which is not 
present in  the 145K fragment. In conclusion, the Fib-2 
domain of human plasma fibronectin is, unlike hamster 
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plasma fibronectin, equally present in both a and p 
subunits, but only the domain present  in  the a subunit 
is released as  the 37K fragment upon tryptic digestion, 
possibly because of the different susceptibility of the 
hinge region between the “cell/Hep-%” (which corre- 
sponds to  the 155K-145K thermolysin fragments) and 
Fib-2  domains. 
FNs’ are a class of high molecular weight glycoproteins 
abundantly present in pericellular matrices and in various 
body fluids, and  their expression on the cell surface is greatly 
affected by oncogenic transformation (1-9). FN can be  char- 
acterized by sharing  a  number of common properties. First, it 
exists as a disulfide-bonded dimer or multimer of identical or 
nonidentical subunit chains with M, = 230,000-210,000. Sec- 
ond, it binds to collagen (or gelatin), fibrin, heparin,  and some 
other glycosaminoglycans, actin, and Staphylococcus aureus, 
and thereby mediates cell attachment and spreading onto 
various substrates. Third, antibodies raised against any  types 
of FN cross-react with other types within the same species. 
However, despite these common properties, FN also shows 
molecular heterogeneity in terms of subunit size and compo- 
sition, solubility, and  structure of carbohydrate  units (9, 10). 
Thus,  FNs from different sources are similar but not identical. 
Several lines of evidence indicate that FN is composed of 
several structural domains which are connected by flexible 
peptide segments (11, 12). Such domains can be  separated by 
mild protease treatment (13-17). Recently, we have shown 
that sequential digestion with trypsin and thermolysin or 
single thermolysin digestion can cleave hamster pFN into four 
distinct domains almost quantitatively (14, 16). These four 
domains, represented by thermolysin fragments with M, = 
150,OOO-140,000,40,000,24,000, and 21,000 (150K-l40K, 40K; 
24K, and 21K fragments), are also distinct from each other in 
their biological functions. These domains are referred to  as 
the  “Hep-l/Fib-1,” “Gel,” “Cell/Hep-2,” and “Fib-2” domain 
in this paper based upon their biological activities. 
Hamster  pFN consists of two nonidentical subunits with M, 
= 230,000 (a  subunit) and 210,000 (p subunit).  Both subunits 
equally contain the Hep-1/Fib-1, Gel, and Cell/Hep-2 do- 
mains, but  the Fib-2 domain has been shown to be  present 
only in the a subunit (16). Thus,  the difference in molecular 
The abbreviations used are: FN, fibronectin; pFN, plasma fibro- 
nectin; NaDodS04, sodium dodecyl sulfate; DBM paper, diazobenzyl- 
oxymethyl paper: PBS, 8.1 mrd NapHP04,  1.5 mM KH*P04, 137 mM 
NaC1,2.7 m KC1, pH 7.4; BSA, bovine serum albumin. 155K is used 
to indicate the fragment of M, = 155,000, for example. 
2The molecular weight of the ‘40K fragment was tentatively 
determined to be 40,000 in the previous paper (14,16),  but it  has now 
























3968 Domain Structure of Human Fibronectin 
weights  between a and p subunits is considered to be due to 
the asymmetric distribution of the Fib-2  domain. 
Human pFN also consists of two nonidentical subunit 
chains, but the apparent difference in molecular  weight  be- 
tween the two subunits is much smaller than that for hamster 
pFN. This raises a question of whether human pFN consists 
of the same set of the domains as hamster pFN, and if so, 
whether the Fib-2 domain is also present only  in the large 
subunit. In  the present investigation, we analyzed the domain 
structure of human pFN by limited proteolysis with trypsin 
and thermolysin and compared it with that of hamster pFN. 
It was found that  the basic  domain  composition  was similar 
between human and hamster pFNs but  the Fib-2  domain  was, 
unlike hamster pFN, present in both large and small subunits 
of human pFN. 
EXPERIMENTAL PROCEDURES 
Materials-Thermolysin (protease, type X), gelatin (from swine 
skin, type I), bovine fibrinogen (type  IV), and soybean trypsin inhib- 
itor were obtained from Sigma; trypsin was from Worthington; bovine 
thrombin was from Dade Diagnostics, Inc. (Miami, FL); Sepharose 
4B and Sephacryl S-200 were from Pharmacia; heparin-agarose was 
from Pierce; DEAE-cellulose was from Whatman  (Kent, England). 
Ultrapure urea was obtained from Schwarz/Mann and was used 
without  further purification. FN-rich supernatant of glycine precipi- 
tation of Fraction 1-1, obtained as a by-product during purification of 
blood coagulation Factor VIII, was kindly provided by Drs. M. W. 
Chopek and K. Fujikawa (Department of Biochemistry, University 
of Washington). Gelatin-Sepharose, soybean trypsin inhibitor-Seph- 
arose, and fibrinogen-Sepharose were prepared according to Cuatre- 
casas and Anfinsen (18). Fibrin-Sepharose was prepared by incubating 
fibrinogen-Sepharose (5 mg  of protein/ml of packed gel) with bovine 
thrombin (1 NIH unit/ml) a t  22 "C for 30 min. The fibrin-Sepharose 
was washed once with 25 mM Tris.HC1 (pH 7.6) containing 8 M urea 
and 0.5 mM EDTA. Nitrocellulose and aminobenzyloxymethyl paper 
were purchased from Bio-Rad. 
Purification ofpFNs-Human and hamster pFNs were purified on 
gelatin-Sepharose from the  supernatant fraction of glycine precipi- 
tation of Factor VI11 and from fresh citrated hamster plasma as 
described previously (16). FNs were eluted from a gelatin-Sepharose 
column with 25 mM Tris-HC1  (pH 7.6) containing 4 M urea and 0.5 
mM EDTA  and dialyzed against 10 n" Tris-HC1 containing 0.5 m~ 
EDTA and 50 m~ NaC1, pH 7.6  ("10 n" Tris buffer"). Human  pFN 
thus purified often contains a small amount of a fragment which 
migrates slightly faster than  the /3 subunit  (see Fig. lB,  lanes b and 
C). 
Purification of Tryptic Fragments-Human pFN (33 mg), dis- 
solved in 10 ml of 10 mM Tris buffer, was digested by trypsin (1 pg/ 
ml)  at 22 "C for 15 min. The digest was quickly passed through a 
soybean trypsin inhibitor-Sepharose column (2.5 X 8 cm) to remove 
trypsin. The digest was then fractionated on gelatin-Sepharose (2.5 
X 9 cm). The bound fragments (215K and 185K fragments) were 
eluted from the column with 25 n" Tris-HC1  (pH 7.6) containing 4 
M urea and 0.5 mM EDTA, dialyzed against 10 mM Tris buffer, and 
concentrated by vacuum dialysis with a Micro-ProDiCon (Bio- 
Molecular Diagnostics, Beaverton, OR). The unbound fragments were 
pooled and applied to a heparin-agarose column (2.5 X 8 cm) equili- 
brated with 10 n" Tris buffer. The bound fragment (32K fragment) 
was eluted with 10 n" Tris.HC1 (pH 7.6) containing 150 n" NaCl 
and 0.5 mM EDTA, dialyzed against 10 mM Tris buffer, and concen- 
trated by vacuum dialysis. The unbound fragment (37K fragment) 
was again pooled and applied to a DEAE-cellulose column (2.5 X 10 
cm). The column was washed with 10 n" Tris buffer and  then  the 
bound fragment (37K fragment) was eluted from the column with 10 
n" Tris. HCl (pH 7.6) containing 150 mM NaCl and 0.5 n" EDTA. 
Anti-37K Fragment Antibodies-The antibodies against purified 
37K fragment were raised in New Zealand White rabbits. Before 
immunization, the 37K fragment, purified by the method described 
above, was further purified by preparative NaDodS04-acrylamide gel 
electrophoresis after reduction with 2% 2-mercaptoethanol. After 
electrophoresis, the gel was briefly stained with 0.25% Coomassie blue 
dissolved in 25% isopropyl alcohol and 10% acetic acid. The 37K band 
was  excised and placed in a dialysis tube filled with electrode buffer 
(ie. 20 mM Tris, 150 m~ glycine, pH 8.3). The fragment was eluted 
from the gel  by electrophoresis and dialyzed against PBS containing 
Bio-Beads SM-2 to remove NaDodSQ. The 37K fragment thus 
purified was emulsified with Freund's complete adjuvant  and injected 
subcutaneously into rabbits a t  multiple sites. Rabbits were immunized 
three times with 100-200  pg  of purified fragment at 2-week intervals. 
The antibodies were affinity-purified on 37K fragment-absorbed 
DBM paper according to Olmsted (19) and also as follows. The 37K 
fragment was first separated on preparative NaDodSO4-polyacry1- 
amide gel electrophoresis and  the 37K band was excised after brief 
staining with Coomassie blue. The fragment was blotted  onto DBM 
paper by electrophoresis according to Towbin et al. (20). The DBM 
paper was incubated with 0.1 M Tris-HC1  (pH 9.0) containing 10% 
ethanolamine and 2.5% BSA to block unbound diazonium  groups. For 
purification of anti-37K antibodies, the  thin strip of DBM paper was 
incubated with 200-fold-diluted antiserum for 2 h a t  22 "C in the 
presence of 5%  BSA. The DBM paper was washed with PBS contain- 
ing 0.05% Triton X-100 four times and  then briefly with PBS. The 
DBM paper was incubated with 10 ml of ice-cold 0.2 M glycine-HC1, 
pH 2.8, for 2 min. The eluted antibodies were quickly neutralized with 
1 M Tris and then mixed with 40 ml of PBS containing 5%  BSA. 
Immunostaining with Anti-37K Antibodies-Intact pFN and its 
proteolytic fragments were separated by NaDodS04-polyacrylamide 
gel electrophoresis and  then transferred to a nitrocellulose sheet by 
electrophoresis. The nitrocellulose sheet was incubated with PBS 
containing 5%  BSA, and  then with affinity-purified antibodies in PBS 
containing 5% BSA for 1 h at  22 "C. The nitrocellulose was washed 
with PBS containing 0.05% Triton X-100 four times. The washed 
nitrocellulose was incubated with '251-protein A in PBS containing 5% 
BSA for 30 min at 22  "C. The nitrocellulose was again washed, dried 
on filter paper, and exposed to Kodak XAR-2 film with an intensifying 
screen. 
NaDodS04-Polyacrylamide Gel Electrophoresis-NaDodS04- 
polyacrylamide gel electrophoresis was performed according to La- 
emmli (21) with 9% gels. Samples were reduced with 2% (v/v) 2- 
mercaptoethanol. The apparent molecular weight was estimated by 
using the following proteins as standards: skeletal muscle myosin, 
200,000, /3-galactosidase, 116,000; phosphorylase b,  94,000; bovine 
serum albumin, 68,000; ovalbumin, 43,000; carbonic anhydrase, 31,000; 
soybean trypsin inhibitor, 21,500, lyoszyme, 14,400. 
RESULTS 
Domain Analysis of HumanpFN-Human pFN consists of 
two nonidentical subunits as is the case  for hamster pFN, but 
the size  difference  between large (a) and small (p) subunits is 
apparently less  pronounced than  that of hamster pFN. When 
analyzed on 8% polyacrylamide gels after prior reduction, 
human pFN gave a single band whereas hamster pFN gave 
clear doublet bands (Fig. L4). Prolonged electrophoresis on 
5% gels, however, could resolve ahurnan pFN into closely 
spaced doublet bands (Fig. 1B) as previously  observed (16,22, 











43- m zm - 
a b c  a b c d  e f  g 
FIG. 1. NaDodS04-polyacrylamide gel electrophoresis of hu- 
m a n  and hamster  pFNs on 8% (A)  and 5% (B) gels. In A,  lane  a, 
molecular weight standards; lane b, human pFN (5 pg); lane C, 
hamster  pFN (5 pg). All samples were reduced by 2-mercaptoethanol. 
In B, lanes a and e, hamster pFN (10 pg); lanes b and f, human  pFN 
(5 pg); lanes c and  g, human  pFN (IO pg); lane  d, skeletal muscle 
myosin. Samples were either reduced (lanes a-d) or not reduced 
(lanes e-g) by 2-mercaptoethanol. The molecular weights of the 
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in two discrete bands with greater separation between the two 
bands than  those from human pFN (Fig. 1B). 
The smaller difference in the molecular weight between a 
and p subunits of human pFN than  that of hamster pFN 
raised a question whether the domain structure of human 
pFN was the same as that of hamster pFN. Previously, we 
found that thermolysin was a good tool to dissect hamster 
pFN into  its constitutive domains (14). Thermolysin digestion 
of human  pFN revealed that  its domain structure was  basi- 
cally the same as  that of hamster  pFN (Fig. 2). It was  cleaved 
into five distinct fragments, each of which corresponded to 
150K, 140K, 40K, 24K, and 21K thermolysin fragments of 
hamster pFN. The molecular weights of each of these  human 
fragments were slightly different from those of corresponding 
hamster fragments, and were tentatively estimated to be 
155,000,145,000,44,000,24,000, and 22,000. In addition, human 
pFN was slightly more resistant to thermolysin than  hamster 
pFN, because it required twice as much of the protease to give 
a comparable digestion profie in the same time period. The 
155K fragment was apparently produced in much lesser 
amounts than the 145K fragment, whereas corresponding 
fragments from hamster pFN were produced in almost equal 
amounts. This could  be due  to the partial degradation of  155K 
fragment into 145K and possibly a fragment with M, = 105,000 
under the condition employed. 
To further confm  that these thermolysin fragments rep- 
resent the same functional domains as represented by corre- 
sponding hamster fragments, the binding properties of these 
fragments were  examined.  Among them, only 44K fragment 
bound to gelatin while other fragments failed to bind (Fig. 3, 
lanes c and d). In  contrast, 155K,  145K, and 24K fragments 
were capable of binding to heparin (Fig. 3, lanes e and f ) ,  and 
24K and 22K fragments were capable of binding to fibrin 
while  155K,  145K, and 44K fragments did not bind to fibrin 
(Fig. 4). All these  results were in good agreement with that of 
155- 
145- w::: ::: -. . .  -. - 
44 - I, ... e... c, 
24 - rn ... # ... 
22 - - e ... - ... - 
a b  c d  e f  
FIG. 3. Binding of thermolysin fragments to gelatin and hep- 
arin. Intact pFN (lane a )  was digested by thermolysin (5 Fg/ml) at 
22 "C for 4 h and the digest (lane  b) was fractionated on gelatin- 
Sepharose (lanes c and d )  or on heparin-agarose (lanes e and f); lane 
c, gelatin-unbound  fragments; lane d, gelatin-bound  fragment; lane e, 












0' 1' 5' 30' l h  4h  4h 
IHAMl 
FIG. 2. Time course of thermolysin digestion of human pFN. 
Human pFN (1 mg/ml) was digested by thermolysin (5 pg/ml) at 
22 "C for different periods of time as indicated below each lane. 
Digestion was terminated by adding EDTA (5 mM). The digest was 
analyzed  by NaDodS04-polyacrylamide gel electrophoresis with prior 
reduction. Right lane is the thermolysin digest of hamster (HAM) 
pFN. 
FIG. 4. Binding of thermolysin fragments to fibrin-Sepha- 
rose. Intact pFN (4.5 mg) was digested by thermolysin (5 pg/ml) at 
22 "C for 4 h and the digest  was  fractionated on a fibrin-Sepharose 
column (2.5 X 8 cm). Lane  a, intact pFN lane b, the thermolysin 
digest; lane c, fibrin-unbound fragments; lane d, fibrin-bound frag- 
ments. 
hamster  pFN (16), c o n f i i n g  that both hamster and human 
pFNs were composed of the same four sets of functional 
domains, i.e. the Hep-1/Fib-1, Gel, Cell/Hep-2, and Fib-2 
domains which correspond to  the 24K,  44K, 155K-l45K, and 
22K fragments, respectively. 
Tryptic  Digestion of Human  pFN: Detection of a Unique 
37K Fragment-Although the basic domain composition was 
identical between human and hamster pFNs  as judged by the 
thermolysin digestion pattern, human pFN gave  upon tryptic 
digestion a significantly different fragment from hamster pFN 
(Fig. 5). A mild trypsin treatment of human pFN produced 
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FIG. 5. Time course of trypsin digestion of human pFN. Hu- 
man pFN (1 mg/ml) was digested by trypsin (1 pg/ml) at 22 "C for 
different  periods  of time as indicated below each lane. Digestion was 
terminated by  adding soybean trypsin  inhibitor (2 pg/ml). The digest 
was analyzed by NaDodS04-polyacrylamide gel electrophoresis on 
9% (A and B)  or 5% (0 gels with (A and 0 or without (B)  prior 
reduction. For each lane, 10 pg  of protein were  applied. The apparent 
molecular weight of major  fragments is shown at the left margin. 
ments  after 10-min digestion, although prolonged treatment 
resulted in the nonstoichiometric degradation of the 215K and 
185K fragments. This profile was very similar to that of 
hamster pFN except that  the 37K fragment was not detected 
in the  latter (16). The time course profile  shown in Fig. 5A 
also suggested that a release of the 32K fragment was  observed 
as early as within 30 s and almost completed after 1 min, 
whereas the release of the 37K fragment was much delayed. 
The 37K was only weakly detected after 1 min, and its 
production reached a plateau after 5-10 min  (Fig. 5A). Further 
analysis of the same sample on a 5% gel (Fig. 5 0  also revealed 
that a high molecular weight fragment with M, = 230,000 was 
transiently generated beside 215K and 185K fragments in the 
early stage of the trypsin digestion. The 230K and 215K 
fragments were produced as early as  after 30 s with concomi- 
tant decrease of intact a and @ subunit chains. Since the 
release of 32K fragment was completed within 1 min, this 
suggests that a and @ subunits were fiist converted into 230K 
and 215K fragments, respectively, by releasing 32K fragment. 
The 230K fragment persisted for 1-2 min and then disap- 
peared after 5-10 min of digestion, while 215K fragment 
appeared to be resistant against further degradation. In ac- 
cordance with the decrease of the 230K transient fragment, 
the 185K fragment gradually increased after 1 min of digestion 
and reached plateau after 5-10 min, suggesting a possible 
precursor-product relationship between 230K and 185K frag- 
ments. Furthermore, this apparent conversion took place 
slowly from 1 min of digestion and was completed after 5-10 
min. This timing apparently coincided with the appearance of 
the 37K fragment. AU these observations, taken together, 
suggest that  the degradation of a and @ subunits of human 
pFN occurred as  the following sequence. 
255K (a) 2 230K  185K 
245K (p)  T215K 
32K 
Another possibility is that  the 230K fragment was sequen- 
tially degraded into 215K and 185K fragments. However, such 
sequential degradation should accompany the release of 
smaller fragments, -15K and -30K, associated with the con- 
version of 230K to 215K and 215K to 185K, respectively. This 
possibility  is,  however, less likely, since the 37K fragment was 
the only fragment detectable in the small molecular  weight 
region in addition to a well established major tryptic 32K 
fragment (16) which is produced by rapid degradation of large 
and small subunit chains into 230K and 215K fragments. 
These trypsin fragments appeared to be  devoid of interchain 
disulfide bridge($, because they exhibited almost the same 
mobility in the acrylamide gels under both reducing and 
nonreducing conditions (Fig. 5B). Since interchain disulfide 
bond($ were shown to be located at  the COOH-terminal ends 
of both subunits, a small COOH-terminal segment which 
contained interchain disulfides must be released during the 
course of the trypsin digestion. Release of the small segment 
appears  to be completed within 5 min  (Fig. 5B). 
Purification and Characterization of the Tryptic Frag- 
ments-The tryptic fragments were separated from each other 
and purified as illustrated in Fig. 6A. The 215K and 185K 
fragments were separated from the 37K and 32K fragments 
on gelatin-Sepharose and further purified by  gel filtration on 
Sephacryl S-200. The 32K fragment was separated from the 
37K fragment on heparin-agarose to which  only the former 
could bind. The 37K fragment, which  passed through heparin- 
agarose, was absorbed on DEAE-cellulose and eluted with 
increasing salt concentration. The relative yield of the 37K 
fragment to the 32K fragment was 0.65:1, based upon the 
absorbance at 280 nm, being almost in agreement with their 
relative intensities on the gel (see Fig. 5A). The binding 
properties of the 215K-185K and 32K fragments were identical 
with the 200K-180K and 32K hamster tryptic fragments, 
respectively (16). 
The purified trypsin fragments were digested by thermoly- 
sin to elucidate their domain composition (Fig. 7). The 215K 
and 185K fragments were predominantly cleaved into 155K- 
145K, 44K, and 22K fragments, although a  part of the 155K- 
145K fragments were further degraded into  a fragment with 
M, = 105,000 (Fig. 723). A fragment which migrated at  the 24K 
fragment position was also faintly detectable (Fig. 7B), but it 
may not be derived from the Hep-1/Fib-1 domain,  because 
this domain of hamster pFN was quantitatively recovered in 
the 32K tryptic fragment (16). Indeed, the human 32K tryptic 
fragment was sequentially converted to 27K and then 24K 
fragments (Fig. 70) .  A fragment which migrated below the 
24K and just above the 22K fragment could be a further 
degradation product of the 24K fragment (Fig. 70) .  The 
degradation profiles of the 215K-185K and 32K tryptic frag- 
ments was essentially identical with that of hamster 200K- 
180K and 32K tryptic fragments (16). The 37K fragment, 
which  was  specific to  human pFN, was  clearly  degraded into 
the 22K fragment by thermolysin (Fig. 7C), suggesting that  it 
contains the Fib-2  domain. 


































FIG. 6. Purification of tryptic fragments. A, diagram of purification of tryptic fragments. B, electrophoretic 
pattern of purified fragments. Lune a,  intact  human  pFN; lune b, tryptic digest; lune c, 215K-185K fragments; lane 
d, 37K fragment; lune e, 32K fragment. 
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FIG. 7. Thermolysin digestion of purified tryptic fragments. 
Intact pFN and its purified tryptic fragments were digested by ther- 
molysin (5 pg/ml) a t  22 "C for different period of time  as indicated 
below each lune. A, intact FN; B, 215K-185K fragments; C, 37K 
fragment; D, 32K fragment. 
domain was tested by fractionating the whole trypsin digest 
on fibrin-Sepharose, because the Fib-2 domain is capable of 
binding to fibrin. As expected, the 37K fragment, as well as 
the 215K and 32K fragments, bound to fibrin (Fig. 8). Only 
the 215K, but  not the 185K, fragment could bind to fibrin. 
This indicates that only the 215K fragment contains the Fib- 
2 domain as was also the case for 200K-180K hamster frag- 
ments (16). The 32K tryptic fragment which contained the 
Hep-1/Fib-1 domain, another fibrin-binding domain present 
at  the NH2 terminus, also could  bind to fibrin. 
Immunostaining of the Proteolytic Fragments with Anti- 
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FIG. 8. Binding of tryptic fragments to fibrin-Sepharose. In- 
tact  pFN (4.5 mg)  was digested by trypsin (1 pg/ml) at 22 "C for 15 
min. The digestion was terminated by adding soybean trypsin inhib- 
itor (2 pg/ml). The digest was fractionated on fibrin-Sepharose (2.5 
X 8 cm) at  4 O C .  The flow rate was 13.5 ml/h. Lune a,  intact pFN, 
lune b, the trypsin digest; lune c, fibrin-unbound fragments; lune d, 
fibrin-bound fragments. 
studied using specific antibodies. Since the 37K fragment, 
which  was  purified according to  the procedure shown in Fig. 
6A, contained a small amount of other fragments, it was 
further purified by preparative gel electrophoresis, and anti- 
bodies against the 37K fragment were raised in rabbits ac- 
cording to the method as described under "Experimental 
Procedures." The antibodies were affinity-purified on 37K- 
blotted and cross-linked DBM paper and then used  for im- 
munostaining of various proteolytic fragments transferred to 
nitrocellulose (Fig. 9). Among the tryptic fragments, the an- 
tibodies strongly stained the 215K and 37K fragments, 
whereas the 185K region  was  only faintly stained (Fig. 9, lane 
b).  A fragment which migrated at  the 43K region was also 
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FIG. 9. Immunostaining of proteolytic fragments by anti- 
37K antibodies. Intact  human pFN (lane a) ,  tryptic  digest (lune b) ,  
and  thermolysin digest (lane c) were  separately  electrophoresed  on  a 
9% gel under  reducing  conditions  in  duplicate.  Gels  were either stained 
by Coomassie blue (A)  or subjected to electrophoretic transfer of 
proteins onto nitrocellulose followed by immunostaining with anti- 
37K antibodies (B) .  For the details, see “Experimental  Procedures.” 
visible upon protein staining. This fragment may correspond 
to a  contaminant fragment in the purified 37K preparation 
which migrated at  the same molecular weight  region (see Fig. 
6B, lane d). The antibodies did not  stain  the 32K fragment 
(Fig. 9, lane b).  These results indicate that  part of the 215K 
fragment overlapped with the 37K fragment, while the 185K 
fragment did not overlap. In addition, immunostaining of 
thermolysin fragments showed that  the 155K and 22K frag- 
ments were specifically stained by the anti-37K antibodies 
(Fig. 9, lane c) .  The fact that  the 155K fragment reacted with 
the anti-37K antibodies but 145K did not  react suggests that 
the antigenic sites include not only the region within the Fib- 
2 domain but also a small polypeptide region of approximately 
10K. This extra 10K  region  which is strongly antigenic must 
be present only in the 155K fragment but  not in the 145K. 
DISCUSSION 
It has been shown that pFNs of any species so far investi- 
gated consist of two nonidentical subunit chains which usually 
give closely spaced doublet bands on NaDodS04-polyacryl- 
amide gels, whereas FNs isolated from the cell surface or 
conditioned medium of fibroblasts appear  to be  composed of 
identical subunit chains (10, 24, 25). The basis of subunit 
heterogeneity of pFN, however, has not been  well understood. 
Recently, we studied the domain structure of hamster pFN 
by limited proteolysis with trypsin and thermolysin (14, 16). 
We found that hamster pFN is composed of at least four 
distinct domains, i.e. 150K-l40K, 40K,  24K, and 21K domains, 
which are now termed Cell/Hep-2, Gel, Hep-1/Fib-1, and Fib- 
2 domains, respectively. The first three domains are equally 
present in both large and small subunits, but  the Fib-2 domain 
appears  to be present only in the large subunit chain. Thus, 
the  subunit heterogeneity of hamster pFN is considered to be 
due to  the asymmetric distribution of the Fib-2 domain. 
In  the present investigation, we studied the domain struc- 
ture of human pFN to see whether such asymmetry in domain 
structure in two subunit chains is a general characteristic for 
other pFNs. In fact, human pFN consists of two nonidentical 
subunit chains, but the apparent difference in molecular 
weight between two subunits is much smaller than  that for 
hamster pFN. Limited proteolysis of human pFN with ther- 
molysin  showed that  the basic  domain  composition  was the 
same  as  hamster pFN. However,  mild tryptic  treatment gave 
a slightly different profile between these pFNs. Besides the 
215K-185K and 32K fragments which were also produced 
from hamster pFN, human pFN gave an additional 37K 
fragment which  was not generated from hamster pFN. 
Several lines of evidence indicated that  the 37K fragment 
contains the Fib-2 domain. First, the 37K fragment was  con- 
verted  to the 22K fragment by thermolysin. Second, both the 
37K fragment and the Fib-2 domain were capable of binding 
to fibrin but  not  to heparin or gelatin. Since the NHz-terminal 
Hep-1/Fib-1 domain, one of the fibrin-binding domains,  was 
almost quantitatively released as a 32K fragment upon  mild 
trypsin treatment, the binding of the 37K fragment to fibrin 
indicates that  it contained another fibrin-binding domain, i.e. 
the Fib-2 domain. Third, affinity-purified anti-37K antibodies 
reacted with the 37K as well as  the 22K thermolysin fragment. 
We also tried to produce specific antibodies against the 22K 
fragment which would be obviously preferable to anti-37K 
antibodies, but we have not yet obtained good antibodies. The 
Fib-2 domain seems to be barely immunogenic under conven- 
tional immunization protocols. 
The alignment of the tryptic fragments was determined as 
schematically illustrated in Fig.  10, by the following reasons. 
First, time course analysis of tryptic digestion of human pFN 
suggested that CY and p subunits were first rapidly cleaved into 
the 230K and 215K fragments, respectively, by releasing the 
Hep-1/Fib-1 domain as  a 32K fragment. The 230K fragment 
was further degraded into the 185K fragment upon the release 
of the 37K fragment. There is extensive  evidence indicating 
that  the 32K fragment containing the Hep-1/Fib-1 domain is 
derived from the NHZ-terminal region of both subunits (22, 
26, 27). In contrast, the 37K fragment contained the Fib-2 
domain which was recently located at  the COOH-terminal 
region of intact subunit chains (28). Thus,  the 185K tryptic 
fragment must be flanked by the 32K and 37K fragments at 
NHz- and COOH-terminal ends, respectively, in the large 
subunit. Both the 215K and 185K fragments contain Gel and 
Cell/Hep-2 domains as shown by thermolysin digestion of 
these  fragment^.^ This was further confirmed with monoclonal 
antibodies specific to 44K and 155K-145K fragments (29). 
The 37K fragment appears to contain not only the Fib-2 
domain but also part of the 155K thermolysin fragment, 
because anti-37K antibodies reacted with the 155K thermol- 
ysin fragment as well. Since the antibodies did not react with 
the 145K fragment, the extra 10K segment present only  in the 
155K fragment should share the same antigenic site(s) with 
the 37K fragment. This indicates that  the order of the four 
domains in CY and /3 subunits should be  NHz-24K-44K-145K- 
tryptic 37K(22K)-COOH and  NHz-24K-44K-155K-22K- 
COOH, respectively (Fig. 10). It should be noted that  the Fib- 
2 domain of human  pFN is, unlike hamster pFN, present in 
both large and small subunit chains. In support of this, both 
(Y and /3 subunits which  were separated on 5%  gels  were almost 
equally reactive with anti-37K antibodies4 
Preliminary experiments suggest that the 155K and 145K frag- 
ments are  generated, respectively, from the 215K and 185K fragments 
upon  thermolysin  digestion. The purified 185K fragment  was  cleaved 
into only 145K and 44K fragments by thermolysin, whereas the 
partially  purified 215K fragment  predominantly  gave 155K, 44K, and 
22K fragments (K. Sekiguchi and S. Hakomori, unpublished obser- 
vation). This is in  good  agreement  with results obtained  with  hamster 
200K-180K fragments (16). 
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Previously, homology between large and small subunits of 
human pFN was studied by one-dimensional (23) or two- 
dimensional (25) peptide mapping, although no significant 
difference has been observed between the subunits. However, 
this technique may not be sensitive enough to detect a subtle 
difference in local amino acid sequence. Indeed, the a subunit 
is apparently 10,000 daltons larger than  the ,8 subunit, but  this 
10,000-dalton extra peptide did not result in any significant 
difference in peptide-mapping pattern. Furthermore, these 
two subunit chains of human pFN showed different suscepti- 
bility to trypsin. Both subunits contain at least two  common 
susceptible sites; one is 32,000 daltons from the NH2 terminus 
and  the  other is near the COOH-terminal end whose  cleavage 
probably results in the release of a small peptide segment 
containing interchain disulfide bond($. In addition, a subunit 
contains another susceptible site which is approximately 
37,000 daltons in distance from the COOH terminus. Since 
time course analysis of trypsin digestion showed that the 
release of the 37K fragment was slower than  that of the NHZ- 
terminal 32K fragment, the additional cleavage site in the 
large subunits  to give the 37K fragment appears to be less 
susceptible to trypsin than other trypsin-sensitive sites. 
Mild trypsin digestion of human pFN has been reported by 
several other groups and very similar fragmentation patterns 
were obtained (30, 31), although a slightly different molecular 
weight  was  assigned  for each tryptic fragment. Smith et al. 
(31) studied the topological arrangement of various tryptic 
fragments of human pFN by affinity chromatography on 
gelatin-Sepharose and heparin-Sepharose as well as immu- 
noaffiity chromatography with monoclonal antibodies with 
different specificities. They suggested that a 31K fragment 
(which appears to correspond to the 37K fragment in the 
present  study) was derived from the COOH-terminal region 
of subunit chains, while a 27K fragment (which seems to 
correspond to  the 32K fragment of this  report) was derived 
from the NH2 terminus. Although they did not assign the 
origin of the 31K fragment to  either the large or small subunit 
chain, these results are in good agreement with our proposed 
model shown in Fig. 10. 
Recently, Richter  and Hormann (32) obtained a 140K frag- 
ment which consists of disulfide-linked 75K and 65K frag- 
ments by cathepsin D digestion. Subsequent plasmin digestion 
of the 140K fragment suggests that only the 75K fragment 
which seems to  be derived from the large subunit contains an 
additional cleavage site at M, = 32,000-36,000 from the 
COOH-terminal end besides another site at the extreme 
COOH-terminal region. This finding further supports our 
proposed model for domain structure of human pFN. 
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